Pulmonx Corporation LUNG Europe, Middle-East and Africa (“EMEA”) — Revenue
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pulmonx Corporation in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Pulmonx Corporation’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pulmonx Corporation's europe, middle-east and africa (“emea”) — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pulmonx Corporation's europe, middle-east and africa (“EMEA”) — revenue?
- Pulmonx Corporation (LUNG) reported europe, middle-east and africa (“EMEA”) — revenue of $6.57M in Q1 2026.
- How has Pulmonx Corporation's europe, middle-east and africa (“EMEA”) — revenue changed year-over-year?
- Pulmonx Corporation's europe, middle-east and africa (“EMEA”) — revenue increased by 19.9% year-over-year, from $5.48M to $6.57M.
- What is the long-term trend for Pulmonx Corporation's europe, middle-east and africa (“EMEA”) — revenue?
- Over 4 years (2021 to 2025), Pulmonx Corporation's europe, middle-east and africa (“EMEA”) — revenue has grown at a 7.9% compound annual growth rate (CAGR), from $19.88M to $26.99M.
- What does europe, middle-east and africa (“EMEA”) — revenue mean?
- This metric represents the total net sales generated from the sale of medical devices and diagnostic platforms within the Europe, Middle-East, and Africa geographic region. It serves as a primary indicator of the company's commercial penetration and market adoption of its minimally invasive respiratory treatments in these international markets. Growth in this figure reflects successful expansion of the installed base and recurring product utilization among healthcare providers in the region.